Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study

NCT03993249 is registered in ClinicalTrials.gov with Hellenic GenitoUrinary Cancer Group as lead sponsor.

NCT NCT03993249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study
Lead sponsor
Hellenic GenitoUrinary Cancer Group
Phase
Phase 2
Overall status
Unknown status
Start date
May 28, 2019
Completion date
December 31, 2023
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer